Credit Suisse Group restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Thursday morning. Credit Suisse Group currently has a $82.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued research reports about the company. TheStreet upgraded Gilead Sciences from a c+ rating to a b- rating in a report on Thursday, September 7th. Deutsche Bank restated a buy rating and set a $81.00 price objective on shares of Gilead Sciences in a report on Thursday, August 31st. Argus upgraded Gilead Sciences from a hold rating to a buy rating and set a $100.00 price objective on the stock in a report on Thursday, August 31st. Berenberg Bank set a $86.00 target price on Gilead Sciences and gave the company a buy rating in a report on Tuesday, August 29th. Finally, Vetr cut Gilead Sciences from a strong-buy rating to a buy rating and set a $82.15 target price on the stock. in a report on Monday, August 28th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $85.11.
Shares of Gilead Sciences (NASDAQ GILD) opened at $74.22 on Thursday. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $96,951.29, a price-to-earnings ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the firm earned $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences will post 8.53 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock worth $37,404,139 over the last three months. 1.30% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Welch Investments LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $108,000. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $133,000. American Beacon Advisors Inc. purchased a new stake in shares of Gilead Sciences during the first quarter worth about $143,000. Finally, Horan Capital Advisors LLC. acquired a new position in Gilead Sciences in the third quarter worth about $144,000. 76.23% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Credit Suisse Group Reaffirms “Buy” Rating for Gilead Sciences (GILD)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/10/credit-suisse-group-reaffirms-buy-rating-for-gilead-sciences-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.